Home » Stocks » CASI

CASI Pharmaceuticals, Inc. (CASI)

Stock Price: $1.18 USD 0.00 (0.00%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $1.20 +0.02 (1.70%) Jul 29, 7:53 PM
Market Cap 164.96M
Revenue (ttm) 17.47M
Net Income (ttm) -53.73M
Shares Out 124.83M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $1.18
Previous Close $1.18
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.20
Day's Range 1.17 - 1.22
Day's Volume 315,211
52-Week Range 1.14 - 3.90

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

1 month ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, May 27, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

2 months ago - PRNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: INFI, ISR, PDSB, SVRA
2 months ago - 24/7 Wall Street

Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 2.1% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 22.22% year over year to ($0.11),...

2 months ago - Benzinga

ROCKVILLE, Md. and BEIJING, May 13, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

2 months ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, May 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

2 months ago - PRNewsWire

Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...

Other stocks mentioned: AVGR, MARK
2 months ago - PennyStocks

ROCKVILLE, Md. and BEIJING, March 30, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

3 months ago - PRNewsWire

Investors don't like that the company is hitting up the market for more cash.

4 months ago - The Motley Fool

ROCKVILLE, Md. and BEIJING, March 24, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

4 months ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, March 23, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

4 months ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, March 11, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

4 months ago - PRNewsWire

Cleave Therapeutics Inc has out-licensed CB-5339 to CASI Pharmaceuticals Inc (NASDAQ: CASI) in mainland China, Taiwan, Hong Kong, and Macau. Cleave and CASI will develop CB-5339 in both hematological ma...

4 months ago - Benzinga

ROCKVILLE, Md. and BEIJING, Jan. 21, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

6 months ago - PRNewsWire

ROCKVILLE, Md., and BEIJING, Jan. 8, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

6 months ago - PRNewsWire

ROCKVILLE, Md., and BEIJING, Dec. 23, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics a...

7 months ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, Nov. 18, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

8 months ago - PRNewsWire

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of CASI Pharmaceuticals (NASDAQ:CASI) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share fell 40.00% over the past year to ($0.14), which missed the e...

8 months ago - Benzinga

ROCKVILLE, MD., and BEIJING, Nov. 5, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

8 months ago - PRNewsWire

CStone Pharma out-licensed global rights (ex-China) for two immuno-oncology assets to US-based EQRx in a $1.3 billion agreement. CASI Pharma in-licensed China rights to a novel antibody checkpoint recep...

Other stocks mentioned: INCY, OCUL, ZLAB
8 months ago - Seeking Alpha

CASI's pipeline expanded to include first-in-class monoclonal antibody developed to unlock anti-cancer immunity in liquid and solid tumors Collaboration accelerates and expands BioInvent's global develo...

9 months ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, Oct. 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

9 months ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, Sept.

10 months ago - PRNewsWire

CASI Pharmaceuticals, Inc. (CASI) CEO Dr.

11 months ago - Seeking Alpha

Shares of CASI Pharmaceuticals (NASDAQ:CASI) moved higher by 1.6% in pre-market trading after the company reported Q2 results.

11 months ago - Benzinga

ROCKVILLE, Md. and BEIJING, Aug.

11 months ago - PRNewsWire

These strong stocks to buy benefited from atypical and big insider buying activity over the past few weeks. The post 5 Stocks to Buy Because of Heavy Insider Buying in July appeared first on InvestorPl...

Other stocks mentioned: FDX, FREQ, GES, LEVI
1 year ago - InvestorPlace

ROCKVILLE, Md. and BEIJING, July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc.

1 year ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, July 21, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc.

1 year ago - PRNewsWire

ROCKVILLE, Md. and BEIJING, June 8, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

1 year ago - PRNewsWire

ROCKVILLE, Md., and BEIJING, June 2, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics an...

1 year ago - PRNewsWire

CASI Pharmaceuticals: 2-Year Price Lows Make For Intriguing Risk-On Buy

1 year ago - Seeking Alpha

CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 20,000 shares of CASI on 08/16/2019 at an average price of $3.2 a share.

1 year ago - GuruFocus

CEO of Casi Pharmaceuticals Inc (30-Year Financial, Insider Trades) Wei-wu He (insider trades) bought 160,000 shares of CASI on 08/14/2019 at an average price of $3.17 a share.

1 year ago - GuruFocus

About CASI

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. The company offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase I studies in China. It also provides CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute ly... [Read more...]

Industry
Biotechnology
IPO Date
Jun 11, 1996
CEO
Wei-Wu He
Employees
144
Stock Exchange
NASDAQ
Ticker Symbol
CASI
Full Company Profile

Financial Performance

In 2020, CASI's revenue was $15.14 million, an increase of 266.52% compared to the previous year's $4.13 million. Losses were -$48.29 million, 4.90% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CASI stock is "Buy." The 12-month stock price forecast is 4.20, which is an increase of 255.93% from the latest price.

Price Target
$4.20
(255.93% upside)
Analyst Consensus: Buy